LCL161

Term ID

CHEBI:193137

Synonyms

(2S)-N-[(1S)-1-cyclohexyl-2-{(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl]-2-(methylamino)propanamide
(S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide
LCL 161
LCL-161
N-[(1S)-1-cyclohexyl-2-{(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl]-N(2)-methyl-L-alaninamide
NVP-LCL161

Definition

LCL161 is a small molecule inhibitor of IAPs that has potent antitumour activity in a range of solid tumours. In HCC, response to LCL161 therapy has shown to be mediated by Bcl-2 expression.

References

cas:1005342-46-0
pubmed:22580047
pubmed:24976294
pubmed:26846923
pubmed:27043662
pubmed:27640787
pubmed:27737687
pubmed:29455885
pubmed:30235087
pubmed:30530779
pubmed:31015310
pubmed:31138375
pubmed:31521127
pubmed:31908904
pubmed:32497533
pubmed:34398333
pubmed:34424319
pubmed:34496878
pubmed:35007560
pubmed:35098674
pubmed:36286042
pubmed:36531039
pubmed:36686801
pubmed:37129455
pubmed:37138866
pubmed:37513508
pubmed:37524969

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from LCL161

Phenotype where environments contain LCL161

Phenotype modified by environments containing LCL161

Phenotype affecting LCL161

Human Disease Model